GT Biopharma Announces Update to OXS-3550 IND Filing, Its Most Advanced Tri-specific Killer Engager May 16, 2018
Gt Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company May 14, 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors April 24, 2018
GT Biopharma, Inc. Announces it has Completed Enrollment in Proof-of-concept Clinical Trial for its Novel Treatment for Motion Sickness April 10, 2018
GT Biopharma Inc. Announces >50% Enrollment in Proof-Of-Concept Clinical Trial For Its Novel Treatment For Motion Sickness March 29, 2018
GT Biopharma, Inc. Announces Additional Positive Data From Its Phase 1 Clinical Trial For Myasthenia Gravis and Potential for Acceleration of the Start of Its Phase 2 Trial March 26, 2018
GT Biopharma (GTBP: OTCQB) Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer February 15, 2018
GT Biopharma Announces Dr. Jeffrey Miller, Renowned NK Cell Cancer Specialist, Will Present at Cell Therapy Symposia February 13, 2018
